IQVIA (NYSE:IQV) Hits New 52-Week High – Here’s What Happened

IQVIA Holdings Inc. (NYSE:IQV) reached a new 52-week high during trading on Thursday. The company traded as high as $278.00 and last traded at $278.3740, with a volume of 21,368 shares traded. The stock had previously closed at $276.63.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of IQVIA from $285.00 to $295.00 in a research report on Wednesday, October 14th. Stifel Nicolaus lifted their price objective on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Leerink Partners increased their price target on IQVIA from $280.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Finally, Weiss Ratings upgraded IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $278.75.

IQVIA Price Performance

The firm has a market capitalization of $46.00 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 2.45 and a beta of 1.17. The business has a fifty day moving average of $263.98 and a two-hundred day moving average of $216.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the previous year, the company posted $2.81 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.54 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 15,581 shares of company stock valued at $3,796,021 over the last ninety days. 1.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IQV. Financial Freedom LLC acquired a new position in shares of IQVIA during the 1st quarter worth $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the 1st quarter worth $25,000. Compass Financial Management LLC bought a new stake in shares of IQVIA during the 2nd quarter worth $27,000. Elevation Wealth Partners LLC boosted its stake in IQVIA by 218.8% in the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after buying an additional 105 shares in the last quarter. Finally, Pension & Wealth Management Advisors Inc. acquired a new stake in IQVIA in the third quarter valued at about $30,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.